All News
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur
Read Article
Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?
https://t.co/XQk17P6D2f https://t.co/y5exrsicW8
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Changing the Conversation with Patients: Lupus
Join the discussion! RheumThoughts are opinion pieces from healthcare professionals.
https://t.co/NcJcCZVlbE
@drbags71 https://t.co/VfAqUkqLak
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Changing the Conversation with Patients: Lupus
https://t.co/rFM2211Toq https://t.co/I9yWGMCH9B
Links:
Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor
When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field.
https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL
Links:
Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor.
Sign up to attend our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN
Links:
Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush RheumNow ( View Tweet)
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB
Links:
Dr. John Cush RheumNow ( View Tweet)
LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication.
🧵1of2 https://t.co/VZL9qJu9kF
Lupus Research LupusResearch ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush RheumNow ( View Tweet)
The AURORA study with voclosporin has changed the way that Dr. Kalunian practices. He now uses lower doses of steroid, 40mg in induction with a faster taper in lupus nephritis. #RNL2023 @RheumNow https://t.co/8ss14Z5WXl
Dr. Rachel Tate uptoTate ( View Tweet)
Reassuring data by Dr. Laurent Arnaud on HCQ
- arrhythmia risk from HCQ similar to general population
@RheumNow #RNL2023 https://t.co/vMDg2SlbJQ
Robert B Chao, MD doctorRBC ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/MwruMhmvPq https://t.co/WnCvCZtq6z
Links:
Dr. John Cush RheumNow ( View Tweet)
BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if this can be a successful combination in lupus nephritis. Dr. Kalunian #RNL2023 @RheumNow https://t.co/XeuybrWigf
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate uptoTate ( View Tweet)
How does HCQ work
@Lupusreference in #RNL2023
HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN
HCQ works as base to increase lysosomal pH and affect cellular function
@RheumNow https://t.co/RTEUF0cS0u
Eric Dein ericdeinmd ( View Tweet)
@Lupusreference in #RNL2023
HCQ and arrhythmia via QTc prolongation
At normal doses, same as general population
If on other QTc prolonging medications, a baseline EKG may be beneficial
@RheumNow https://t.co/cAN2vBNa1t
Eric Dein ericdeinmd ( View Tweet)
Any dose more than 1500 is associated with retinopathy ? So what to do. @Lupusreference #RNL2023 @RheumNow https://t.co/2zdjpcuvKa
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
